KMM-1
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
The KMM-1 cell line is a lymphocyte-like human multiple myeloma cell line that exhibits plasma cell characteristics. It displays a small round-cell morphology with some multinucleate cells, growing in suspension with noticeable nucleoli and rough endoplasmic reticulum. The cells possess an abnormal karyotype characterized by 47, X, 
-Y, Iq+, -2, +t(1:2) (cen:cen), +7, 12q+, 14q+, +mar, and lack Epstein-Barr virus-determined nuclear antigen. Surface markers include E rosette (-), IgG Fc receptor (-), C3 receptor (-), S-Ig (+), TdT (-), and asialo-GM1 (-). Notably, KMM-1 cells are shown to secrete immunoglobulins into the culture medium.
Why choose KMM-1 from AcceGen?
The KMM-1 cell line from AcceGen is characterized by its high viability and quality, maintained under optimal culture conditions. It is sterile and rigorously tested negative for mycoplasma, bacteria, fungi, and human pathogens. The cell line is efficiently preserved using advanced cryopreservation techniques.
| Product Code | KMM1 |
| Species | Human |
| Cat.No | ABC-TC0517 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Multiple Myeloma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Myeloma Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
KMM-1 cells find diverse applications in research, notably in investigating antioxidant, antiproliferative, and immunostimulatory effects. They serve as a valuable model to study cancer cell apoptosis induction by potential inhibitors. Additionally, they are integral in preclinical trials involving immunophenotypic and immunotypic evaluations. Furthermore, KMM-1 cells hold promise in evaluating potential therapeutic agents, including therapeutic small guide RNAs, against multiple myeloma, contributing significantly to advancing therapeutic strategies in this context.
